133 related articles for article (PubMed ID: 35076103)
1. Relationship between patient acceptable symptom state and disease scores in psoriasis.
Wang Q; Lu W; Luo Y; Tan M; Zhu W; Kuang Y; Shen M
J Dermatol; 2022 Apr; 49(4):448-453. PubMed ID: 35076103
[TBL] [Abstract][Full Text] [Related]
2. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
3. The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis.
Fei JZ; Perruccio AV; Ye JY; Gladman DD; Chandran V
Rheumatology (Oxford); 2020 Jan; 59(1):69-76. PubMed ID: 31199486
[TBL] [Abstract][Full Text] [Related]
4. Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort.
Walsh JA; McFadden M; Woodcock J; Clegg DO; Helliwell P; Dommasch E; Gelfand JM; Krueger GG; Duffin KC
J Am Acad Dermatol; 2013 Dec; 69(6):931-7. PubMed ID: 24054760
[TBL] [Abstract][Full Text] [Related]
5. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.
Golbari NM; van der Walt JM; Blauvelt A; Ryan C; van de Kerkhof P; Kimball AB
J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):417-421. PubMed ID: 32978847
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice.
Merola JF; Amato DA; See K; Burge R; Mallinckrodt C; Ojeh CK; Gottlieb A
J Invest Dermatol; 2018 Sep; 138(9):1955-1961. PubMed ID: 29577919
[TBL] [Abstract][Full Text] [Related]
7. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
Bożek A; Reich A
Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
[TBL] [Abstract][Full Text] [Related]
8. Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis.
Gottlieb AB; Germino R; Herrera V; Meng X; Merola JF
Dermatology; 2019; 235(4):348-354. PubMed ID: 31141807
[TBL] [Abstract][Full Text] [Related]
9. Detection of Small Changes in Psoriasis Intensity with PrecisePASI.
Kolios AG; French LE; Navarini AA
Dermatology; 2015; 230(4):314-7. PubMed ID: 25765296
[TBL] [Abstract][Full Text] [Related]
10. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
[TBL] [Abstract][Full Text] [Related]
11. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis.
Henseler T; Schmitt-Rau K
Int J Dermatol; 2008 Oct; 47(10):1019-23. PubMed ID: 18986347
[TBL] [Abstract][Full Text] [Related]
12. Defining threshold values on the neck disability index corresponding to a patient acceptable symptom state in patients undergoing elective surgery for degenerative disorders of the cervical spine.
Goh GS; Yue WM; Guo CM; Tan SB; Chen JL
Spine J; 2020 Aug; 20(8):1316-1326. PubMed ID: 32445806
[TBL] [Abstract][Full Text] [Related]
13. Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
Am J Clin Dermatol; 2017 Aug; 18(4):583-590. PubMed ID: 28342016
[TBL] [Abstract][Full Text] [Related]
14. Psoriasis Severity Assessment Combining Physician and Patient Reported Outcomes: The Optimal Psoriasis Assessment Tool.
Leonardi C; See K; Gallo G; McKean-Matthews M; Zhang Y; Goldblum O; Mallbris L; Burge R
Dermatol Ther (Heidelb); 2021 Aug; 11(4):1249-1263. PubMed ID: 34047947
[TBL] [Abstract][Full Text] [Related]
15. Treating to Target-A Realistic Goal in Psoriasis?
Gordon KB; Armstrong AW; Menter MA; Wu JJ
Semin Cutan Med Surg; 2018 Feb; 37(2S):S44-S47. PubMed ID: 29614137
[TBL] [Abstract][Full Text] [Related]
16. Validation of a simple measure of psoriasis severity based on a longitudinal study of Chinese patients.
Cao D; Shen M; Chen X; Xiao Y; Lu W; Luo Y; Zhu W; Kuang Y
Eur J Dermatol; 2020 Dec; 30(6):674-679. PubMed ID: 33459259
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin for the treatment of plaque-type psoriasis.
Faghihi T; Radfar M; Mehrabian Z; Ehsani AH; Rezaei Hemami M
Pharmacotherapy; 2011 Nov; 31(11):1045-50. PubMed ID: 22026392
[TBL] [Abstract][Full Text] [Related]
18. Body surface area measurement and soft clustering for PASI area assessment.
Hani AF; Prakasa E; Nugroho H; Affandi AM; Hussein SH
Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():4398-401. PubMed ID: 23366902
[TBL] [Abstract][Full Text] [Related]
19. Measurement of circulating miRNA-125a exhibits good value in the management of etanercept-treated psoriatic patients.
Pei D; Cao J; Qin G; Wang X
J Dermatol; 2020 Feb; 47(2):140-146. PubMed ID: 31820498
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Patient-reported Outcomes in Patients with Psoriatic Arthritis (PsA) by Body Surface Area Affected by Psoriasis: Results from the Corrona PsA/Spondyloarthritis Registry.
Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
J Rheumatol; 2017 Aug; 44(8):1151-1158. PubMed ID: 28620063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
